Event Profile

Go Back

This course focuses on the ongoing evolution of US value assessment frameworks from conventional cost-effectiveness analysis (CEA) to the ISPOR Value Flower, on to Generalized and Risk-Adjusted Cost-E...

This course will present steps for a successful implementation of PROs in the drug development process that includes: PRO instrument selection, psychometric evaluation, data capture, and interpretatio...

This course will present the design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials based on, in part, "Good Research Practices for Cost-Effectiveness Analysis alongsi...

This highly practical course will outline the computational and transparency advantages of using R for health economic modelling compared to MS Excel. The highly experienced faculty will lead particip...

The rapid advancement of Generative AI offers transformative potential in HEOR. This course provides participants with an introduction to Generative AI models, focusing on large language models (LLMs)...

Throughout this course, participants will gain insights into how DHPs can emerge as a fresh source of RWE, specifically applicable for informing pricing and reimbursement decision making across variou...

This course teaches using R for model-based cost-effectiveness analysis (CEA). Implementation of Markov cohort, partitioned survival, and individual patient simulations will be covered. Participants w...

This course will introduce innovative causal inference approaches for the design and analysis of big real-world observational data and pragmatic trials. Topics include causal diagrams (DAGs), target t...

This course introduces Al's role in processing medical records, addressing foundational challenges and practical applications, including data access and privacy. It covers technical complexities with ...

Many CGTs have the potential to offer transformative benefits for patients. However, at launch there is often resistance from payers to reimburse these therapies due to limitations in the supporting e...

The value of medical innovation varies by stakeholder perspective. Registration authorities focus on clinical value for patients. Payers focus on economic value, including equity, and reward value to ...

Participants will get a broad view of the Generalized Risk Adjusted Cost Effectiveness (GRACE) model for health technology evaluation. Current uses of standard CEA and concerns raised by that model wi...